Reviva Net Working Capital from 2010 to 2025

RVPHW Stock  USD 0.05  0.01  12.43%   
Reviva Pharmaceuticals Net Working Capital yearly trend continues to be fairly stable with very little volatility. Net Working Capital is likely to outpace its year average in 2025. During the period from 2010 to 2025, Reviva Pharmaceuticals Net Working Capital regression line of quarterly data had mean square error of 61.3 T and geometric mean of  8,059,996. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
7.5 M
Current Value
10.8 M
Quarterly Volatility
10.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Reviva Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 10 K, Net Interest Income of 602.5 K or Interest Income of 602.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 20.25. Reviva financial statements analysis is a perfect complement when working with Reviva Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.

Latest Reviva Pharmaceuticals' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Reviva Pharmaceuticals Holdings over the last few years. It is Reviva Pharmaceuticals' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Reviva Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Reviva Net Working Capital Regression Statistics

Arithmetic Mean378,752
Geometric Mean8,059,996
Coefficient Of Variation2,846
Mean Deviation8,990,736
Median(6,813,837)
Standard Deviation10,779,862
Sample Variance116.2T
Range35.9M
R-Value0.71
Mean Square Error61.3T
R-Squared0.51
Significance0
Slope1,612,710
Total Sum of Squares1743.1T

Reviva Net Working Capital History

202510.8 M
20247.5 M
20236.5 M
202212.9 M
202129.1 M
20207.4 M

About Reviva Pharmaceuticals Financial Statements

Reviva Pharmaceuticals investors use historical fundamental indicators, such as Reviva Pharmaceuticals' Net Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Reviva Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital7.5 M10.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Reviva Stock Analysis

When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.